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Early detection of renal dysfunction is of importance in 
the care of critically ill patients. Cystatin C was proposed 
to be superior to serum creatinine in estimation of renal 
function. This work aimed to compare serum cystatin C 
to serum creatinine and creatinine based formulae in 
detection of early decline in renal function at a single 
point in critically ill patients. Fifty critically ill patients 
admitted to Cairo University Hospitals ICUs - Egypt- 
were included. Patients with chronic renal disease, 
thyroid disease, malignancy, patients receiving 
corticosteroid therapy, with serum creatinine > 1.4 mg/dl 
and patients receiving diuretics or large volumes of IV 
fluids were excluded. Serum creatinine, serum cystatin 
C, adjusted creatinine clearance (Adj Ccr), estimated 
GFR (eGFR) by modification of diet in  renal disease 
(MDRD), abbreviated MDRD (abb MDRD) and 
Cockcroft-Gault (CG) formulae were measured. Patients 
with renal dysfunction (adj Ccr < 80 ml/min/1.73m
2
) 
were 26 (52%) in number. Patients with renal 
dysfunction and high serum creatinine were 12/26 
(46.2%)  while those with high cystatin C were 23/26 
(88.5%). Cystatin C was found to be significantly 
correlated with serum creatinine, adj Ccr and eGFR by 
all studied formulae. Using receiver operating 
characteristic (ROC) analysis; AUC for Cystatin C 
(0.976) was more than that for eGFR by abb MDRD 
(AUC=0.839), MDRD (AUC=0.822), CG formulae 
(AUC=0.808) and serum creatinine (AUC=0.710) 
respectively. In conclusion; cystatin C was found to be 
better than serum creatinine, eGFR by abb MDRD, 
MDRD and CG formulae in detection of early renal 
dysfunction at a single point in critically ill patients. 
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Assessment and follow up of renal function is an integral 
part of medical care of ICU patients. Serum creatinine 
level is affected by many other factors than renal 
function as muscle mass, gender, age, diet and tubular 
secretion [1]. In cases of acute kidney injury, there is no 
enough time for creatinine to accumulate in serum and 
for serum creatinine level to reflect the degree of renal 
dysfunction. So, the major benefit of serum creatinine 
appears to be mainly in stable patients [2]. Determination 
of GFR with high adequacy requires the use of specific 
techniques based on measuring clearance rate of an 
injected substance such as inulin or 
51
Cr-EDTA [3]. In 
order to avoid the use of invasive methods, several 
equations depending on serum creatinine and other 
variables have been developed for calculation of GFR 
[4]. Cystatin C is a member of cystatin superfamily of 
cystein protease inhibitors that had been proposed as a 
marker of GFR and was proposed to be superior to serum 
creatinine especially in cases of mild renal insufficiency 
[5,6]. Using the clearance of radioisothalamate as the 
gold standard, serum cystatin C began increasing at GFR 
level of ~ 90 ml/min/1.73 m
2
 while serum creatinine only 
increased when GFR was ~ 70 ml/min/1.73 m
2
 [7]. In the 
settings of acute kidney injury in critically ill patients, 
Cystatin C was found in some studies to be more 
sensitive and of superior diagnostic value in detection of 
mild decrease in GFR than serum creatinine while in 
others it was not found to have such a significance [8-
11]. This study aimed to compare the ability of serum 
cystatin C to serum creatinine and creatinine based 
formulae in detection of early renal function decline at a 
single point in critically ill patients.  
  
2 
Material and methods 
 
The protocol of this study was first approved by the 
scientific board of Nephrology Division - Internal 
Medicine Department and Committee of Research 
Ethics; Faculty of Medicine – Cairo University - Egypt.  
Fifty patients were included who were admitted to 
different ICUs in Cairo University Hospitals. Informed 
consents were obtained either from the patient himself or 
a first degree relative in the case of patient inability. 
Clinical characteristics of patients are illustrated in 
table(1). Excluded patients were those with chronic renal 
disease, thyroid disease, malignancy and patients 
receiving corticosteroid therapy due to expectedly high 
serum cystatin C [12-14]. Patients with serum creatinine 
more than 1.4 mg/dl and patients receiving diuretics or 
large volumes of IV fluids were also excluded.  
Urine collection was done over a 24 hour period using 
indwelling urinary catheter starting from 8:00 am to 8:00 
am next day; the time at which a blood sample was taken 
for estimation of serum creatinine, blood urea nitrogen 
(BUN), serum albumin and serum cystatin C.  
Measurement of serum cystatin C was done using 
RD191009100 human Cystatin C ELISA.  
Adjusted creatinine clearance (Adj Ccr) was calculated 
using the following equation [3]:  
Adj CCr (ml/min/m
2
) = [(24 hour urine volume X urine 
creatinine)/ (Serum creatinine X 1440)] X 1.73/ 
calculated BSA.  
Body surface area (BSA) = √[Ht (cm)  x Wt (kg)  /  360]  
[15].  
Glomerular filtration rate (ml/min) was estimated 
(eGFR) using the following equations:  










 X 0.762 (if female). 
Abbreviated MDRD (abb MDRD) formula [16]: 
GFR = 186 x serum creatinine (mg/dl)
-1.154
 x age (years)
-
0.203   
X 0.742 for females. 
Cockcroft-Gault (CG) formula [17]: 
              (140 - age) x lean body weight [kg] X (0.85 for females) 
GFR =  ——————————————————————— 
                                            Cr [mg/dl] x 72 
Adjusted creatinine clearance was used as a reference for 
GFR in our study. A level 0f 80 ml/min/1.73m
2
 was used 
as a cut off value for renal dysfunction [4,7]. 
Statistical methods: 
Data were statistically described in terms of range, 
mean± standard deviation (SD), median and 95%CI of 
the mean. Categorical data were summarized as 
percentages. Pearson's correlation coefficient was used to 
measure the strength of association between two 
variables. Accuracy was represented using the terms 
sensitivity and specificity. Receiver operator 
characteristic (ROC) analysis was used to determine the 
optimum cut off value for the studied diagnostic markers. 
All P-values are two-sided. P-values < 0.05 were 
considered significant. Data management and analysis 
were performed using Statistical Analysis Systems 
{(Microsoft Excel 2003 (Microsoft Corporation, NY, 
USA) and Stats Direct statistical software version 2.7.2 




Mean ± SD of laboratory parameters of patients enrolled 
in our study are illustrated in table 1. 
 








Age (mean ±SD) 
Sex (male/female) 
Diagnosis (number %): 
     Acute MI  
     Respiratory failure 
     Hepatic coma 
     Intracerebral hemorrhage 
     Status epilepticus 
     Post CABG 
     Sepsis 
APACHE II score (mean ± SD) 
Serum creatinine (mean ± SD)  (n=0.5 – 1.4 mg/dl) 
Serum cystatin C (mean ± SD)  (n= 620 – 1150 ng/l) 
Adjusted Creatinine clearance (mean ± SD) (ml/ min/1.73m2) (mean ± SD) 
eGFR by CG formula (ml/min) (mean ±SD) 
eGFR by MDRD formula (ml/min) (mean ±SD) 
eGFR by abb MDRD formula (ml/min) (mean ±SD) 
 
 
51.9 ±13.9 y (15-86 y) 
30/20 (60 / 40 %) 
 
25pt (50%) 
6 pt (12%) 
6 pt (12%) 
2 pt (4%) 
1 pt (2%) 
1 pt (2%) 
1 pt (2%) 
14.23 ± 6.77 
1.102 ± 0.283 mg/dl 
1175.8 ± 702.2 ng/l  
87.24 ± 48.93 ml/ min/1.73m2 
87.46 ± 39.58 ml/min 
65.2 ± 31.72 ml/min 
77.24 ± 37.45 ml/min 
 
Patients with adj Ccr > 80 ml/min/1.73m
2
 were 24 (48%) 
in number while patients with adj Ccr < 80 
ml/min/1.73m
2
 were 26 (52%) in number. Among 
patients with low adj Ccr, number of patients with 
elevated level of serum cystatin C was found to be higher 
than number of patients with elevated serum creatinine. 
Regarding patients with adj Ccr > 80 ml/min/1.73m
2
; 
number of patients with elevated serum creatinine was 
found to be slightly higher than those with elevated 
























Fig. 1. Number of patients with normal and elevated serum creatinine and serum cystatin C levels in critically ill patients with renal dysfunction (adj Ccr < 
80 ml/min/1.73m2 , number =26) and in patients with adj Ccr > 80 ml/min/1.73m2 (number = 24). 
 
Serum cystatin C was found to be significantly correlated 
with serum creatinine, adj Ccr and eGFR by all 
creatinine based formulae (figure 2). Similarly, adjusted 
creatinine clearance was found to have significant 
correlation with serum creatinine (r=   -0.604, p<0001) 
and creatinine based formulae (p<0001 for all). Using 
receiver operating characteristic plots (ROC) for analysis 
of diagnostic values of both serum cystatin C and 
creatinine based methods; area under the curve (AUC) 
for cystatin C was found to be higher than that for serum 
creatinine and other creatinine based formulae indicating 
better diagnostic ability for serum cystatin C than other 
methods in detecting renal dysfunction at a cut off value 
of adjusted creatinine clearance of 80 ml/min/1.73m
2
 





Table 2. Receiver operating characteristic (ROC) analysis for serum cystatin C and other creatinine based methods in detection of renal dysfunction (adj 





abb MDRD formula  
 






























































Fig. 2. Correlations of serum cystatin C to serum creatinine, adjusted creatinine clearance (adj Ccr), eGFR by modification of diet in renal disease 





Fig. 3. Receiver operating characteristic plots (ROC curve) for sensitivity and specificity of serum cystatin C and creatinine based formulae in detecting 
early renal dysfunction (adj Ccr < 80 ml/min/1.73m2). Area under the curve for serum cystatin C is higher than creatinine based methods. 




Early detection of renal dysfunction is of extreme 
importance in directing management of critically ill 
patients. There are many limitations the use of serum 
creatinine for this purpose including delay of rise after 
considerable affection of GFR. Cystatin C production in 
the body is a stable process for which it was suggested to 
be an ideal endogenous marker representing GFR [18, 
19].  
In our study, area under the curve for serum cystatin C 
was found to be larger than that for serum creatinine. 
Also, number of patients with high serum cystatin C was 
higher than those with high serum creatinine among 
patients with renal dysfunction detected by adj Ccr. 
Thus,  serum cystatin C was found to be better than 
ROC plot for creatinine in diagnosing early renal  dysfunction









ROC plot for cystatin-Cin diagnosing early renal  dysfunction










ROC plot for MDRD in diagnosing early renal  dysfunction









ROC plot for modified MDRD in diagnosing early renal  dysfunction










ROC plot for CG formula in diagnosing early renal  dysfunction












serum creatinine in detection of renal dysfunction in 
critically ill patients at our used cut off value of adj Ccr. 
Moreover, cystatin C was found to be better correlated 
with adj Ccr than serum creatinine. The diagnostic utility 
of cystatin C seen in our study was close to what was 
previously reported by other investigators. In a study 
done by Villa and her associates, 50 critically ill patients 
were included. Their number of patients with renal 
dysfunction was nearly similar to us (25 vs 26). Our 
patients with renal dysfunction having a high level of 
serum cystatin C were higher than those of the study of 
Villa et al (23 vs 19). However, in their study and ours 
this was higher in number than patients with high serum 
creatinine. Similar to ours, higher AUC for serum 
cystatin C than for serum creatinine was found in 
critically ill patients [20-21]. Earlier rise of serum 
cystatin C than serum creatinine was found in patients 
developing renal dysfunction [22]. In a comment on the 
study of Villa et al, the use of adj Ccr as a control for 
GFR was disagreed and the use of more accurate 
methods for GFR detection as inulin and isothalamate 
clearances was advised. [23]. Most studies conducted to 
evaluate whether there is a role for serum cystatin C in 
determining GFR involved measurement of the clearance 
of an exogenous substances such as  
51
Cr -EDTA as the 
gold standard [24]. Nevertheless, creatinine clearance 
could be considered as a reliable marker for determining 
GFR on a routine basis, and multiple studies used 
creatinine clearance as a control for evaluating the role 
for serum cystatin C as a measure of GFR [21,25]. In our 
study, we also used adjusted creatinine clearance as a 
reference for evaluating GFR inspite of its limitations 
due to its relative simplicity and convenience in critically 
ill patients. Urine collection was done using indwelling 
urinary catheter avoiding bias of urine collection and 
patients receiving large volumes of IV fluids or diuretic 
therapy were excluded.  
In the current study serum cystatin C was found to be 
better than creatinine based formulae including CG 
formula, MDRD and abb MDRD formulae in detection 
of renal dysfunction. A cystatin C prediction equation 
was found to be equally sensitive or slightly better than 
MDRD formulae in predicting GFR in a large number of 
patients with variable diagnoses [26, 27]. In patients with 
native kidney disease; cystatin C was found to be better 
correlated with GFR than MDRD and CG equations [28]. 
Similar to what was found in critically ill patients [29] 
and renal transplant recipients [30] we found that serum 
cystatin C was significantly correlated with serum 
creatinine, adj Ccr, GFR calculated by abb MDRD, 
MDRD, and with CG formulae.  
In addition to the use of Adj Ccr as the gold standard for 
GFR, another limitation of the current study was the use 
of single assessment of renal functions both for cystatin 
C and creatinine based methods. Serial measurements of 
serum creatinine and cystatin C are better done to detect 
decline of renal functions in such dynamic unstable 
patients. Moreover, a more specific formula that takes 
into consideration fluctuations in serum creatinine such 
as Jelliffe equation, which can be adjusted to daily fluid 
balance, seems to be better for the study of changes in 
renal functions in unstable critically ill patients than CG 
or MDRD formulae [31]. 
Conclusion; serum cystatin C was found to be better than 
serum creatinine, eGFR by abb MDRD, MDRD and CG 
formulae in detection of early renal dysfunction at a 
single point in critically ill patients. Further studies are 
recommended to further clarify these points using a more 
specific gold standard for estimation of GFR than 
adjusted creatinine clearance and including a serial 
follow up of studied data with a larger number of 
patients. 
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